It was found that the expression of activated NK cell receptors such as NKp30, NKG2D, DNAX accessory molecule-1 (DNAM-1), and CD16 was reduced in cancers, while the expression of inhibitory receptors such as NKG2A was increased in cancers such as breast cancer [35]. This evidence concerns the gene CD226 and breast carcinoma.